Catalyst Brief

← Calendar

Readoutin 76d

Janssen Research & Development, LLC — Nipocalimab

Phase 3 primary completion: Nipocalimab in Moderate to Severe Sjogren's Disease.

Date
Feb 2027
Type
Readout
Indication
Sjogrens Syndrome

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Janssen Research & Development, LLC

  1. Dec2026
  2. Dec2026